Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Angélica Kloberg"'
Autor:
Michael Matousek, Sara Forsmark, Olof Zachrisson, Angélica Kloberg, Robert C. Schuit, Marie Nilsson, Carl-Gerhard Gottfries, Maria L. Carlsson, Birgitta Peilot, Arvid Carlsson
Publikováno v:
Acta Neuropsychiatrica, 148-157. Cambridge University Press
STARTPAGE=148;ENDPAGE=157;ISSN=0924-2708;TITLE=Acta Neuropsychiatrica
Nilsson, M K L, Zachrisson, O, Gottfries, C G, Matousek, M, Peilot, B, Forsmark, S, Schuit, R C, Carlsson, M L, Kloberg, A & Carlsson, A 2018, ' A randomised controlled trial of the monoaminergic stabiliser (−)-OSU6162 in treatment of myalgic encephalomyelitis/chronic fatigue syndrome ', Acta Neuropsychiatrica, pp. 148-157 . https://doi.org/10.1017/neu.2017.35
STARTPAGE=148;ENDPAGE=157;ISSN=0924-2708;TITLE=Acta Neuropsychiatrica
Nilsson, M K L, Zachrisson, O, Gottfries, C G, Matousek, M, Peilot, B, Forsmark, S, Schuit, R C, Carlsson, M L, Kloberg, A & Carlsson, A 2018, ' A randomised controlled trial of the monoaminergic stabiliser (−)-OSU6162 in treatment of myalgic encephalomyelitis/chronic fatigue syndrome ', Acta Neuropsychiatrica, pp. 148-157 . https://doi.org/10.1017/neu.2017.35
ObjectiveThe monoaminergic stabiliser (−)-OSU6162 has in previous studies shown promising effects on mental fatigue after stroke and traumatic brain injury. This study investigated the safety and effectiveness of (−)-OSU6162 in patients with myal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bfe76bdcc0ec756f1f3891fd010591
https://pubmed.ncbi.nlm.nih.gov/29212562
https://pubmed.ncbi.nlm.nih.gov/29212562
Autor:
Johan P. Rung, Maria L. Carlsson, Arja Schedwin, Sarah Hansson, Angélica Kloberg, Marie Nilsson, Arvid Carlsson, Ethan S. Burstein
Publikováno v:
Journal of Neural Transmission. 118:1511-1522
The locomotor effects of (-)- and (+)-OSU6162 were evaluated in 'low activity' animals (reserpinized mice and habituated rats) and 'high activity' animals (drug-naive mice and non-habituated rats). Both enantiomers of OSU6162 had dual effects on beha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7ff032f071dc1aafab6a6210431452
https://doi.org/10.1007/s00702-011-0704-8
https://doi.org/10.1007/s00702-011-0704-8
Autor:
Angélica Kloberg, Jan Wahlström, Sara Haghighi, Maria L. Carlsson, Marie Nilsson, Arvid Carlsson, Radu Constantinescu
Publikováno v:
Acta neuropsychiatrica. 26(5)
ObjectiveTo evaluate the safety (primary objective) and efficacy (secondary objective) of (−)-OSU6162 in Huntington’s disease (HD).MethodsIn a double-blind, cross-over trial, patients with HD were randomly assigned to start treatment on either (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ffa6ea47df3f5cc4f9c9059285e1671
https://pubmed.ncbi.nlm.nih.gov/25241758
https://pubmed.ncbi.nlm.nih.gov/25241758